Estradiol propionate reduction of nuclear size in prostate cancer lines lacking DHRS7suggests DHRS7 absence as a biomarker for the effectiveness of estrogen therapy
Rizzotto, A.; Tollis, S.; Pham, N. T.; Zheng, Y.; Abad, M. A.; Wildenhain, J.; Jeyaprakash, A. A.; Auer, M.; Tyers, M. D.; Schirmer, E. C.
Show abstract
Increased nuclear size correlates with lower survival rates for prostate cancer and is a hallmark of late-stage androgen-insensitive tumors. The short-chain dehydrogenase/reductase (SDR) family member DHRS7 was suggested as a marker for prostate cancer grading because it is lost in late-stage androgen-insensitive tumors. Here we find that loss of DHRS7 from the early-stage LNCaP prostate cancer cell line increases nuclear size, potentially explaining the nuclear size increase observed in higher-grade prostate tumors. Exogenous expression of DHRS7 in the late-stage PC3 prostate cancer cell line correspondingly decreases nuclear size. We separately tested 80 compounds from the Microsource Spectrum library for their ability to restore normal nuclear size to PC3 cells, finding estradiol propionate had the same effect as re-expression of DHRS7 in the PC3 cells. However, the drug had no effect on LNCaP cells or PC3 cells re-expressing DHRS7. We speculate that reported beneficial effects of estrogens in late-stage prostate cancer may target a pathway which is only active in cells lacking DHRS7 that have increased nuclear size and propose DHRS7 as a potential biomarker for the likely effectiveness of estrogen-based treatments.
Matching journals
The top 13 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Gαq-stimulated gene expression is insensitive to Bromo extra terminal domain inhibitors in HEK 293 cells 93%
- Pro-apoptotic and anti-invasive properties underscore the tumor suppressing impact of myoglobin on subset of human breast cancer cells 92%
- Identification of a cardiac glycoside exhibiting favorable brain bioavailability and potency for reducing levels of the cellular prion protein 92%
Similar papers in this journal
- RUNX1 is regulated by androgen receptor to promote cancer stem markers and chemotherapy resistance in triple negative breast cancer. 93%
- Systemic ablation of Camkk2 impairs metastatic colonization and improves insulin sensitivity in TRAMP mice: Evidence for cancer cell-extrinsic CAMKK2 functions in prostate cancer 93%
- HSP90α and KLK6 Co-Regulate Stress-Induced Prostate Cancer Cell Motility 92%
Similar papers in this journal
- Increased nuclear factor I/B expression in prostate cancer correlates with AR expression 94%
- RELA is Sufficient to Mediate Interleukin-1 (IL-1) Repression of Androgen Receptor Expression and Activity in LNCaP Disease Progression Model 93%
- Use of Droplet Digital PCR for Consistent Detection of TMPRSS2:ERG Gene Fusion Transcripts Initiated In Vitro 92%
Similar papers in this journal
- ECD, a novel androgen receptor target promotes prostate cancer tumorigenesis by regulating glycolysis 95%
- Androgen Receptor Signaling Regulates the Transcriptome of Prostate Cancer Cells by Modulating Global Alternative Splicing 94%
- MEIS1 down-regulation by MYC mediates prostate cancer development through elevated HOXB13 expression and AR activity 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.